KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance

被引:0
|
作者
Song Zheng
Ke-er Huang
Yue-long Pan
Yao Zhou
Song-dan Pan
Xin Li
Jing Jia
Xiao-liang Zheng
De-you Tao
机构
[1] The First People’s Hospital of Hangzhou,Department of Oncology, Hangzhou Cancer Hospital
[2] Zhejiang University,Department of Emergency, Second Affiliated Hospital, School of Medicine
[3] Zhejiang Academy of Medical Sciences,Department of Oncology
[4] Taizhou Hospital of Zhejiang Province,undefined
来源
Gastric Cancer | 2015年 / 18卷
关键词
Gastrointestinal stromal tumor; KIT; BRAF; Rhabdomyosarcomatous differentiation; Imatinib resistance;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:796 / 802
页数:6
相关论文
共 50 条
  • [1] KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance
    Zheng, Song
    Huang, Ke-er
    Pan, Yue-long
    Zhou, Yao
    Pan, Song-dan
    Li, Xin
    Jia, Jing
    Zheng, Xiao-liang
    Tao, De-you
    GASTRIC CANCER, 2015, 18 (04) : 796 - 802
  • [2] KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
    Miranda, Claudia
    Nucifora, Martina
    Molinari, Francesca
    Conca, Elena
    Anania, Maria Chiara
    Bordoni, Andrea
    Saletti, Piercarlo
    Mazzucchelli, Luca
    Pilotti, Silvana
    Pierotti, Marco A.
    Tamborini, Elena
    Greco, Angela
    Frattini, Milo
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1769 - 1776
  • [3] Effect of KIT mutations on response to imatinib in gastrointestinal stromal tumors
    Nature Clinical Practice Oncology, 2006, 3 (8): : 411 - 411
  • [4] KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1146 - 1147
  • [5] Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
    Rossi, Sabrina
    Sbaraglia, Marta
    Dell'Orto, Marta Campo
    Gasparotto, Daniela
    Cacciatore, Matilde
    Boscato, Elena
    Carraro, Valentina
    Toffolatti, Luisa
    Gallina, Giovanna
    Niero, Monia
    Pilozzi, Emanuela
    Mandolesi, Alessandra
    Sessa, Fausto
    Sonzogni, Aurelio
    Mancini, Cristina
    Mazzoleni, Guido
    Romeo, Salvatore
    Maestro, Roberta
    Dei Tos, Angelo P.
    ONCOTARGET, 2016, 7 (21) : 30109 - 30118
  • [6] Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations
    Haller, Florian
    Detken, Sven
    Schulten, Hans-Juergen
    Happel, Nicole
    Gunawan, Bastian
    Kuhlgatz, Jens
    Fuezesi, Laszlo
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 526 - 532
  • [7] Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by Secondary KIT Mutations
    Florian Haller
    Sven Detken
    Hans-Jürgen Schulten
    Nicole Happel
    Bastian Gunawan
    Jens Kuhlgatz
    László Füzesi
    Annals of Surgical Oncology, 2007, 14 : 526 - 532
  • [8] Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
    Wardelmann, E
    Merkelbach-Bruse, S
    Pauls, K
    Thomas, N
    Schildhaus, HU
    Heinicke, T
    Speidel, N
    Pietsch, T
    Buettner, R
    Pink, D
    Reichardt, P
    Hohenberger, P
    CLINICAL CANCER RESEARCH, 2006, 12 (06) : 1743 - 1749
  • [9] Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects
    Kalfusova, Alena
    Linke, Zdenek
    Kalinova, Marketa
    Krskova, Lenka
    Hilska, Irena
    Szabova, Jana
    Vicha, Ales
    Kodet, Roman
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [10] KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors -: Reply
    Heinrich, Michael C.
    Corless, Christopher L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1147 - 1148